Heidi Henson - 23 Dec 2021 Form 3 Insider Report for PARDES BIOSCIENCES, INC.

Role: Chief Financial Officer
Signature: /s/ Elizabeth Lacy, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 23 Dec 2021
Net transactions value: $0
Form type: 3
Filing time: 27 Dec 2021, 16:42:31 UTC
Next filing: 02 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	PRDS	Common Stock						316,753	23 Dec 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	PRDS	Stock Option (Right to Buy)							23 Dec 2021	Common Stock	241,593	$3.88	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/4th of the shares subject to such option vest and become exercisable on January 20, 2022, and 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on the 20th day of each month thereafter, subject to a continued service relationship.

Remarks:

Exhibit 24 - Power of Attorney Effective immediately following the effective time of the merger pursuant to that certain Agreement and Plan of Merger dated as of June 29, 2021, as amended, by and among Pardes Biosciences Sub, Inc. (f/k/a Pardes Biosciences, Inc.), Issuer (f/k/a FS Development Corp. II), and certain other parties thereto, the reporting person became an officer of the Issuer.